☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MHRA advice on rosiglitazone

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a statement following the publication of a meta-analysis in the New England Journal of Medicine linking rosiglitazone with cardiovascular events.

The publication of the original paper has already been covered, as has the FDA response to the study.

The MHRA have highlighted that the product information for rosiglitazone has carried warnings about heart failure since 2000 and myocardial infarction since 2006.

The MHRA advice is that "patients should not stop treatment with rosiglitazone but should discuss their medication with their doctor at their next routine appointment".

Action: Clinicians should be aware of the MHRA advice and discuss alternative treatment options with patients currently taking rosiglitazone at their next routine appointment.

Share 'MHRA advice on rosiglitazone' by emailShare 'MHRA advice on rosiglitazone' on FacebookShare 'MHRA advice on rosiglitazone' on TwitterShare 'MHRA advice on rosiglitazone' on LinkedInShare 'MHRA advice on rosiglitazone' on reddit


One Comment to “MHRA advice on rosiglitazone”

  1. […] fails to provide any reassurance with respect to the cardiovascular safety of rosiglitazone. MHRA advice recommends that patients currently taking rosiglitazone discuss the risks and benefits of continued […]

    Pingback by Rosiglitazone defence unconvincing | Prescribing Advice for GPs — June 6, 2007 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.